<DOC>
	<DOCNO>NCT00274313</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability new inhale sodium-channel blocker call 552-02 teen adult cystic fibrosis . 552-02 inhaled day 14 day use nebulizer . A small subgroup patient donate blood sample pharmacokinetic analysis see 552-02 absorbed blood eliminate 14 day treatment .</brief_summary>
	<brief_title>Safety Study Inhaled 552-02 Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Male female patient age &gt; 14 year . 2 . Patients diagnose cystic fibrosis . 3 . Patients FEV1 ≥ 50 % predict ( postbronchodilator ) screening . 4 . Patients able perform reproducible spirometry accord ATS guideline . 5 . Patients oxygen saturation ≥ 92 % room air determine pulse oximetry screening . 1 . Patients FEV1 change ≥ 15 % bronchodilator use screening . 2 . Patients unstable lung disease define requirement intravenous antibiotic four week prior screen , change medical regimen within 14 day prior administration first dose study drug 14 day treatment period , FEV1 ≥ 15 % recent ( within six month ) clinical measurement , significant new finding chest radiograph ( pneumothorax , lobar/segmental collapse ) consider part usual , chronic progression cystic fibrosis lung disease . 3 . Patients angiotensin convert enzyme ( ACE ) inhibitor . 4 . Patients renal insufficiency evidence hyperkalemia ( blood potassium level great 5.5 mEq/L ) serum creatinine &gt; 2.0 mg/dL . 5 . Patients history drug allergy medicine chemically relate study drug ( e.g . amiloride , Moduretic , Midamor ; triamterene ) . 6 . Patients pregnant , positive pregnancy test , nursing . 7 . Patients lung transplant .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>